The role of miR-342-3p in myocardial fibrosis of chronic heart failure by targeting CRIM1
Year: 2026
Type: article
Study design: Observational Study
Abstract: Chronic heart failure (CHF) is characterized by myocardial fibrosis as its core pathological feature, yet effective therapeutic targets for this process remain limited. A total of 85 CHF patients and 73 healthy controls were included to measure the expression of miR-342-3p and CRIM1 in peripheral blood and to evaluate their clinical relevance. In in vitro experiments, miR-342-3p mimics and CRIM1 overexpression were used to functionally assess TGF-β1-induced fibrosis in human cardiac fibroblasts. Comprehensive experiments, including qPCR, CCK-8, Transwell, and dual-luciferase reporter assays, demonstrated that miR-342-3p regulates fibroblast proliferation, migration, and the expression of fibrosis-related genes by targeting CRIM1. Clinical analysis indicates that peripheral blood miR-342-3p expression in CHF patients is significantly lower than in healthy controls, while CRIM1 expression is significantly higher. Both are associated with clinical indicators such as heart function classification, BNP, LVEF, and LAVI. miR-342-3p showed potential diagnostic value for CHF, and its low expression was associated with an unfavorable prognosis. In vitro experiments found that TGF-β1 inhibits miR-342-3p expression, while overexpression of this miRNA promotes cell proliferation and migration and reduces the levels of fibrosis markers. Mechanistically, CRIM1 has been confirmed as a direct target of miR-342-3p, mediating its anti-fibrotic effect. miR-342-3p is downregulated in CHF and inhibits cardiac fibrosis by targeting CRIM1, suggesting that it may serve as a novel diagnostic marker and potential therapeutic target for CHF.
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,890
OpenAlex ID: W7236303125
